Home › Funds › PSP Research LLC › CLDX

PSP Research LLC position in CLDX

CELLDEX THERAPEUTICS INC NEW · Health Care

PSP Research LLC reported holding 13,000 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q2 2026 13F filing — a position valued at US$484K, representing 0.26% of its reported portfolio and ranking #22 among its reported holdings. PSP Research LLC has disclosed CLDX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)13.00K sh
Reported value held$483.73K
Portfolio Weight0.26%
First reportedQ4 2025
Last changeNew

How PSP Research LLC's CLDX position evolved

PSP Research LLC first disclosed a stake in CLDX in Q4 2025 at 20,368 shares (US$553K). Across 3 filings, PSP Research LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 13,000 shares valued at US$484K. Notable position changes include a 36% trim in Q1 2026 (shares rose 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 20.37K $553.20K New
Q1 2026 13.00K $412.36K Reduce
Q2 2026 13.00K $483.73K New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CLDX and 13F data

CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 44 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CLDX

All CLDX fund holders →